Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 21-25

  Lord, Brian ^a   Wintmolders, Cindy ^a   Langlois, Xavier ^a   Nguyen, Leslie ^a   Lovenberg, Tim ^a   Bonaventure, Pascal ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Autoradiography; GluN2B; Ketamine; NMDA; Receptor occupancy

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; DIZOCILPINE; ELIPRODIL; IFENPRODIL; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRAXOPRODIL; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; EX VIVO STUDY; HIPPOCAMPUS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AUTORADIOGRAPHY; GLUN2B; KETAMINE; NMDA; RECEPTOR OCCUPANCY;

ANIMALS; BINDING SITES; HIPPOCAMPUS; KETAMINE; MALE; MICE; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84885474450     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.028     Document Type: Article

References (30)

1. Anand, A., Gunn, A.D., Barkay, G., Karne, H.S., Nurnberger, J.I., Mathew, S.J., Ghosh, S., 2012. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 14, 64-70.
2. Barbier, A.J., Aluisio, L., Lord, B., Qu, Y., Wilson, S.J., Boggs, J., Bonaventure, P., Miller, K., Fraser, I., Dvorak, L., Pudiak, C., Dugovic, C., Shelton, J., Mazur, C., Letavic, M. A., Carruthers, N.I., Lovenberg, T.W., 2007. Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. Eur. J. Pharmacol. 576, 43-54. (Pubitemid 47588256)
3. Chazot, P.L., Hawkins, L.M., 1999. NMDA receptor subtypes - rationale for future CNS therapies. IDrugs 2, 1313-1326.
4. Chenard, B.L., Shalaby, I.A., Koe, B.K., Ronau, R.T., Butler, T.W., Prochniak, M.A., Schmidt, A.W., Fox, C.B., 1991. Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J. Med. Chem. 34, 3085-3090.
5. Cyr, M., Thibault, C., Morissette, M., Landry, M., Di Paolo, T., 2001. Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuropsychopharmacology 25, 242-257. (Pubitemid 32566346)
6. Dingledine, R., Borges, K., Bowie, D., Traynelis, S.F., 1998. The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61. (Pubitemid 29113865)
7. Gogas, K.R., 2006. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 6, 68-74. (Pubitemid 43103821)
8. Guscott, M.R., Clarke, H.F., Murray, F., Grimwood, S., Bristow, L.J., Hutson, P.H., 2003. The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur. J. Pharmacol. 476, 193-199. (Pubitemid 37272147)
9. 3H]ifenprodil binding to sigma receptors in rat brain. Eur. J. Pharmacol. 236, 159-163. (Pubitemid 23146865)
10. Hashimoto, K., London, E.D., 1995. Interactions of erythro-ifenprodil, threo-ifen-prodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur. J. Pharmacol. 273, 307-310.
11. Henson, M.A., Larsen, R.S., Lawson, S.N., Pérez-Otaño, I., Nakanishi, N., Lipton, S.A., Philpot, B.D., 2012. Genetic deletion of NR3A accelerates glutamatergic synapse maturation. PLoS ONE 7.
12. Ishima, T., Hashimoto, K., 2012. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors. PLoS ONE 7.
13. Kobayashi, T., Washiyama, K., Ikeda, K., 2006. Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology 31, 516-524. (Pubitemid 43276967)
14. Langlois, X., te Riele, P., Wintmolders, C., Leysen, J.E., Jurzak, M., 2001. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J. Pharmacol. Exp. Ther. 299, 712-717. (Pubitemid 32979686)
15. Loftis, J.M., Janowsky, A., 2003. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97, 55-85. (Pubitemid 35477804)
16. Machado-Vieira, R., Salvadore, G., Ibrahim, L.A., Diaz-Granados, N., Zarate Jr., C.A., 2009. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des. 15, 1595-1611.
17. Murck, H., 2013. Ketamine, magnesium and major depression - from pharmacology to pathophysiology and back. J. Psychiatr. Res. 47, 955-965.
18. 3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur. J. Pharmacol. 397, 263-270. (Pubitemid 30323777)
19. 3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neuro-chem. 70, 2147-2155. (Pubitemid 28207840)
20. Ogden, K.K., Traynelis, S.F., 2011. New advances in NMDA receptor pharmacology. Trends Pharmacol. Sci. 32, 726-733.
21. Ozawa, S., Kamiya, H., Tsuzuki, K., 1998. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54, 581-618. (Pubitemid 28123327)
22. Pringle, A., Parsons, E., Cowen, L.G., McTavish, S.F., Cowen, P.J., Harmer, C.J., 2012. Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist mem-antine. J. Psychopharmacol. 26, 1417-1423.
23. Reynolds, I.J., Miller, R.J., 1989. Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. Mol. Pharmacol. 36, 758-765. (Pubitemid 20008223)
24. 3H]ifenprodil, a novel NMDA antagonist, to a polyamine-sensitive site in the rat cerebral cortex. Eur. J. Pharmacol. 176, 249-250. (Pubitemid 20041302)
25. Schotte, A., de Bruyckere, K., Janssen, P.F., Leysen, J.E., 1989. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res. 500, 295-301. (Pubitemid 19257048)
26. Schotte, A., Janssen, P.F., Megens, A.A., Leysen, J.E., 1993. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 63, 191-202. (Pubitemid 24009988)
27. Schotte, A., Janssen, P.F., Bonaventure, P., Leysen, J.E., 1996. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem. J. 28, 791-799. (Pubitemid 26414169)
28. Whittemore, E.R., Ilyin, V.I., Woodward, R.M., 1997. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. J. Pharmacol. Exp. Ther. 282, 326-338. (Pubitemid 27425558)
29. Yamakura, T., Shimoji, K., 1998. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog. Neurobiol. 59, 279-298.
30. Zarate Jr, C.A., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., Manji, H.K., 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry. 63, 856-864. (Pubitemid 44188478)